Filter posts

Biobuck M&A in Full Gear

The 2012 M&A results are in and trends are mixed. Last year was a down …

Choose Your Own Adventure – The Private Biotech Crossroads

It is a known fact within the private company biopharma universe that the days of …

BIO Europe Spring 2012 - Opening Remarks

For Monday’s Opening Remarks at BIO Europe Spring 2012, I covered the following topics: Public …

Venture Capital increases in 2011, but...

The National Venture Capital Association (NVCA) has released their 4Q 2011 numbers for biotech venture …

Public Exits and Virtual Biotechs - Dreams or Reality?

Here at the 10th Annual BIO Investor Forum, investors and CEOs are debating “all the …

IPO Update - April 5th, 2011

The six biotech IPOs of 2011 have followed 2010’s IPO trends; all took significant haircuts getting …

Anitbody Deals Peaked in 2007

Antibody and antibody-like scaffold molecules have been on the pharma licensing radar for some time. …

2011, The Year of Positive Thinking? BIO/IPREO Study Reveals High Hopes for the Industry

BIO CEO’s closing plenary session featured plenty of crystal ball gazing and candid quips about …

Release of BIO/Biomedtracker Drug Approval Rates Study

BIO and BioMedTracker are pleased to present the findings of their joint clinical trial success …

Clinical Trial Success Rates - Recent Study from Tufts

Joseph DiMasi and his team at Tufts University published a paper earlier this year in …